Key result
Stepwise lipid-modulating therapies optimize cardiovascular risk targets in women.
Answers are grounded in this paper and cite their sources.
Epidemiological and therapeutic studies of cardiovascular disease have revealed definite gender differences with respect to risk factors, disease onset and intensity of treatment, in part related to complex hormonal-issues. Numerous studies have shown that in clinical practice, recognition and therapeutic reduction of cardiovascular risk in women is substantially less well done than that with men. In this paper, by reviewing data from therapeutic trials which enrolled women, including those using estrogen and standard lipidmodulating drugs, and by discussing lipoprotein trafficking abnormalities prevalent in women, we will outline more aggressive, stepwise therapeutic approaches likely necessary to achieve lipid and lipoprotein goals. Integral to a discussion of such aggressive treatment is a review of drug mechanisms of action as currently understood.
No takes yet. Share an insight, caveat, or question.
Dayspring et al. (2007) conducted a review in Cardiovascular risk in menopausal women. Pharmacotherapy (estrogen and lipid-modulating drugs) was evaluated. This review outlines more aggressive, stepwise pharmacotherapeutic approaches, including estrogen and lipid-modulating drugs, to achieve lipid and lipoprotein goals in women with cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: